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The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a
consortium of researchers at Seattle BioMed, Emerald BioStructures, the
University of Washington and Paciﬁc Northwest National Laboratory that was
established to apply structural genomics approaches to drug targets from
infectious disease organisms. The SSGCID is currently funded over a ﬁve-year
period by the National Institute of Allergy and Infectious Diseases (NIAID) to
determine the three-dimensional structures of 400 proteins from a variety of
Category A, B and C pathogens. Target selection engages the infectious disease
research and drug-therapy communities to identify drug targets, essential
enzymes, virulence factors and vaccine candidates of biomedical relevance to
combat infectious diseases. The protein-expression systems, puriﬁed proteins,
ligand screens and three-dimensional structures produced by SSGCID con-
stitute a valuable resource for drug-discovery research, all of which is made
freely available to the greater scientiﬁc community. This issue of Acta
Crystallographica Section F, entirely devoted to the work of the SSGCID,
covers the details of the high-throughput pipeline and presents a series of
structures from a broad array of pathogenic organisms. Here, a background is
provided on the structural genomics of infectious disease, the essential
components of the SSGCID pipeline are discussed and a survey of progress
to date is presented.
1. Structural genomics of infectious disease: a short history
Over the past decade, structure-based drug design has played an
increasingly important role in drug development. To this end,
considerable effort and resources have been devoted to solving
important protein structures from human pathogens (Van Voorhis et
al., 2009), leading to the establishment of several structural genomics
consortia. The ﬁrst group, the Structural Genomics of Pathogenic
Protozoa Consortium (SGPP; http://www.sgpp.org/) solved 70 struc-
tures of proteins from pathogenic protozoa, developing methods
and insights that were subsequently used by the Medical Structural
Genomics of Pathogenic Protozoa Project (MSGPP; http://
www.msgpp.org/) to develop novel antiprotozoan drugs (Fan et al.,
2008). The Tuberculosis Structural Genomics Consortium (TBSGC;
http://www.webtb.org/) uniﬁes core facilities to service more than 100
individual laboratories and focuses on the structure determination
of metabolic and other functionally important proteins from Myco-
bacterium tuberculosis to aid in drug discovery (Goulding et al., 2002;
Terwilliger et al., 2003). Although the Structural Genomics Consor-
tium (SGC; http://www.sgc.utoronto.ca/) focuses heavily on human
diseaseproteins, this group also studies kinases, cylophilins, ubiquitin-
conjugating enzymes and a number of salvage and biosynthesis
pathways from eukaryotic parasites, including trypanosomes, Plas-
modium falciparum and their apicomplexan orthologues (Gileadi et
al., 2007; Bochkarev & Tempel, 2008). The Viral Infection Structural
Proteomics(VISP)Center(http://visp.scripps.edu/default.aspx)solves
protein structures from SARS-CoV, inﬂuenza, herpesviruses and
ﬂaviviruses. In addition, the biological community has nominated a
number of microbial targets for structure solution by the Protein
Structure Initiative (PSI) network (http://www.sbkb.org/). In parti-
cular, the Midwest Center for Structural Genomics (MCSG; http://
www.mcsg.anl.gov/) addresses proteins related to pathogenesis,metabolism, host interactions and disease (Lee et al., 2011). By
September 2007, these cumulative efforts and those from individual
research laboratories had resulted in over 3700 Protein Data Bank
entries for proteins from pathogenic organisms on the NIAID
Category A, B and C Priority Pathogens list, excluding Escherichia
coli.
In late 2007, the National Institute of Allergy and Infectious
Diseases (NIAID) provided funding to both the Seattle Structural
Genomics Center for Infectious Disease (SSGCID; http://
www.ssgcid.org) and the Center for Structural Genomics of Infectious
Diseases (CSGID; http://www.csgid.org/) to solve protein structures
from potential bioterrorism agents and emerging and re-emerging
infectious disease organisms (Myler et al., 2009; Anderson, 2009).
These organisms include 31 different genera of bacteria, eukaryotes
and viruses, which have been divided between the two centers. In
striving to meet the needs of infectious disease researchers within
the greater scientiﬁc community, the SSGCID interacts heavily with
academic collaborators to solicit target nominations and to freely
provide for them structural data, as well as clones, puriﬁed proteins
and other laboratory materials, for primary research purposes
(Myler et al., 2009). The work of the SSGCID, the CSGID and other
specialized centers represents an increased focus within the National
Institutes of Health to address a broad range of biological problems
relevant to particular sectors of scientiﬁc investigation. Thus, the
SSGCID represents a unique structural biology resource for
researchers focused on the discovery and development of novel cures
or treatments for infectious diseases.
2. SSGCID: the Seattle Structural Genomics Center for
Infectious Disease
The SSGCID consortium consists of team members from four insti-
tutions in the Paciﬁc Northwest of the United States: Seattle
Biomedical Research Institute (Seattle BioMed), Emerald Bio-
Structures (EmBios, formerly deCODE bioStructures), the Univer-
sity of Washington (UW) and Paciﬁc Northwest National Laboratory
(PNNL). The consortium is advised by an external panel of experts,
and a Target Selection Board reviews targets selected by the con-
sortium itself prior to submission to NIAID for approval. Community
requests for novel protein structures are reviewed and approved by
NIAID with the highest priority prior to entry into the SSGCID
structure-determination pipeline. The SSGCID workﬂow is divided
into several major activities: Target Selection, Cloning and Expres-
sion Testing, Protein Production, Crystallization, X-ray and NMR
Data Collection, Structure Solution, and Project and Data Manage-
ment. The ﬁrst will be described brieﬂy below, with the remaining
activities explored in more detail in the Laboratory, Crystallization
and Structure Communications contained in this volume of Acta
Crystallographica Section F.
2.1. Target selection
SSGCID focuses its structure-determination efforts on eight
genera of bacteria (Bartonella, Brucella, Ehrlichia, Anaplasma,
Rickettsia, Burkholderia, Mycobacterium and Borrelia), nine species
of eukaryotic pathogens (Acanthamoeba, Babesia, Cryptosporidium,
Cyclospora, Toxoplasma, Giardia, Entamoeba, Coccidioides and
Encephalitozoon), 13 negative-strand RNA viruses (Marburg virus,
Ebola-like virus, inﬂuenza A, B and C viruses, Arenavirus, Hanta-
virus, Henipavirus, Lyssavirus, Nairovirus, Orthobunyavirus, Phle-
bovirus and Rubulavirus) and one single-stranded DNA virus
(Erythrovirus). To date, a total of 7564 targets from 65 species within
24 genera have been validated and approved for the SSGCID pipe-
line. At the outset of this project, the SSGCID bioinformatics team
selected several thousand proteins thought to represent drug targets
in SSGCID target organisms since they play key roles in, or were
identiﬁed as markers of, infectivity, reproduction, growth and drug
introduction
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Figure 1
The SSGCID pipeline. A 17-tiered serial escalation approach is utilized by the SSGCID, with activities performed at Seattle BioMed (pink), UW-PPG (blue), Emerald
BioStructures (green) and UW-NMR or PNNL (orange). Each Tier utilizes the approach described at the bottom of the ﬁgure. The numbers in the hexagons indicate the
numbers of targets which have successfully passed through each step of the pipeline.resistance. For bacterial and eukaryotic pathogens, initial target
selections were made by identifying homologues to potential drug
targets in a single ‘representative’ species/strain from each genus
based on similarity to targets in the DrugBank database (http://
www.drugbank.ca/). Additional details covering the initial target-
selection approaches, including the bioinformatic ﬁlters utilized, have
been described previously (Myler et al., 2009). Target selection at
SSGCID also includes rescue attempts for failed targets by selecting
orthologues or paralogues in other species within the NIAID-
approved genera. This has been performed for eight Mycobacterium
genomes (M. abscessus, M. avium, M. bovis, M. leprae, M. marinum,
M. paratuberculosis, M. smegmatis and M. thermoresistibile) in order
to characterize homologues of M. tuberculosis targets which had
failed at some stage within the SSGCID pipeline. We have also used a
bioinformatic approach that utilizes a statistical classiﬁcation algo-
rithm (Cadag et al., 2008) to identify proteins predicted to be asso-
ciated with virulence and/or pathogenesis. Viral genomes contain
substantially fewer protein-coding genes than bacterial or eukaryotic
pathogens and therefore a different approach was adopted for target
selection in these genera. Following the recommendation of the viral
research community, we focused on two potential drug targets
involved in viral replication: nucleoprotein (N) and RNA-dependent
RNA polymerase (L). Orthologues of these targets were selected
from several genera, species or strains for each virus family. This
strategy has already been applied to the Bunyaviridae, Para-
myxoviridae and Rhabdoviridae families and will be extended to
Arenaviridae, Orthomyxoviridae and Parvoviridae.
As awareness of the SSGCID has permeated the scientiﬁc
community, the pipeline of internally selected targets has become
supplemented with increasing numbers of targets requested by
community researchers. Interaction with collaborative researchers
continues to inﬂuence the SSGCID pipeline, leading to the selection
of entire biological pathways that appear to be essential in one or
morepathogenic organisms. For instance, several communityrequests
included all seven enzymes of the methylerythritol phosphate (MEP)
pathway for isoprenoid biosynthesis from a number of bacterial and
protozoan species. Enzymes in this pathway have been demonstrated
to be essential in malaria, tuberculosis and a variety of other proto-
zoan and bacterial organisms, in contrast to the mevalonate-
dependent pathway that is present in humans (Rohmer et al., 1993;
Jomaa et al., 1999; Eisenreich et al., 2004; Hunter, 2007). SSGCID has
also expanded beyond proteins to include a small number of
noncoding RNA molecules, such as bacterial thi-box, SAM-II and
preQ1 riboswitches, for structure determination. This work includes
efforts to determine the structure of a ligand-bound viral RNA
complex identiﬁed by the UW-NMR group together with a commu-
nity collaborator. Such noncanonical macromolecular complexes
represent ground-breaking efforts to expand the range of biological
targets amenable to drug targeting and represent efforts to better
understand biological mechanisms which are essential for the growth
and proliferation of infectious disease organisms.
2.2. Structure-determination pipeline
The methodologies used within SSGCID for cloning, expression
testing, protein production, crystallization and structure determina-
tion have been described previously (Myler et al., 2009), with further
detail and recent improvements described in the accompanying
articles. Most targets entering the SSGCID pipeline (Fig. 1) are
cloned into the SSGCID standard bacterial expression vector
(pAVA0421) by PCR ampliﬁcation from genomic DNA or cDNA
(Tier 1). A relatively small percentage of target plasmids come
directly from collaborators (Tier 0) or are cloned using gene synthesis
(Tier 3). Multiple rescue pathways (Tiers 2–9) allow increased success
in either expression or puriﬁcation with any target and are prioritized
for community-request targets. With puriﬁed protein in hand, crys-
tallization trials are set up in standard screens using two 96-condition
sparse-matrix screens and two 96 grid-condition screens. In addition,
a substantial number of SSGCID proteins have been screened using
the Microcapillary Protein Crystallization System (MPCS) developed
by the Protein Structure Initiative (PSI) ATCG3D technology center
(Gerdts et al., 2008, 2010). High-priority small-molecular-weight
targets that fail to crystallize are selected for NMR-based analysis
and structure determination at PNNL or UW-NMR (Tier 10). For
every unique macromolecular structure solved by the SSGCID,
model coordinates and structure factors are deposited in the Protein
Data Bank (http://www.pdb.org) to provide the broadest possible
public access (Berman et al., 2000, 2003). Every apoprotein structure
successfully solved is then bioinformatically processed in an attempt
to ﬁnd putative cofactors, inhibitors or other ligands for cocrystalli-
zation trials. This process employs biochemical searches for enzyme-
reaction substrates and cofactors by mining databases that contain
ligand or potential inhibitor interactions. Chemical abstract service
(CAS) numbers or other identiﬁers are then used to query vendor
databases for ordering. In addition to targeted ligand-complex
studies, SSGCID annually selects a small number of high-impact
targets for a complete Fragments-of-Life library screen (Tier 12;
Begley, Davies et al., 2011; Davies et al., 2009). This library now
introduction
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Figure 2
Cumulative status at key steps of targets in the SSGCID pipeline.contains over 2000 metabolites, their bioisosteres and other small
molecules designed to mimic compounds found within the natural
metabolome. Studies with high-priority SSGCID targets have led
to the reﬁnement of fragment-based screening techniques by NMR
spectroscopy (Begley, Davies et al., 2011) and X-ray crystallography
(Begley, Hartley et al., 2011). Lastly, RNA targets enter Tier 16 and
protein complexes enter Tier 17, with special protocols adapted for
pipeline production of these classes of macromolecules (Fig. 1).
2.3. Target status and success rates
To date, 7564 targets have been approved for entry into the
SSGCID structure-determination pipeline (Fig. 2), including 1384
which were either nominated or claimed by the scientiﬁc community.
The SSGCID has cloned a total of 4178 targets, of which 2376 have
expressed soluble protein and 1483 have been prepared to high purity
from cell extracts. Of these, 726 have yielded crystals amenable to
X-ray diffraction, resulting in X-ray structures for 226 targets.
Heteronuclear single-quantum coherence (HSQC) spectra have been
acquired for an additional 34 targets, 14 of which have led to
complete solution-state structure determination by standard protein-
based NMR experiments. These 240 different targets have led to 318
structures being submitted to the PDB, of which 112 (from 70 targets)
contained bound ligands. The overall structure-determination success
rate for the 3383 bacterial, 758 eukaryotic and 37 viral targets cloned
by SSGCID currently stands at 6%, but the success rate varies
considerably (from 1 to 18%) between genera (Table 1). While the
solubility rate is surprisingly similar for prokaryotes and eukaryotes
(57 versus 56%, respectively), some bacteria (Borrelia and Rickettsia)
and a number of eukaryotes (Cryptosporidium, Encephalitozoon,
Entamoeba, Giardia and Toxoplasma) perform relatively poorly.
Interestingly, the puriﬁcation success rates are lower for prokaryotes
(60%) than eukaryotes (71%); this may be the result of a large
number of soluble Burkholderia targets having not yet been puriﬁed.
Crystallization and diffraction rates from eukaryotic proteins are
lower (44% and 43%, respectively) than those from prokaryotes
(51% and 51%, respectively). However, once high-quality diffraction
data have been obtained the rates of structure solution are similar for
both kingdoms.
3. Community outreach
3.1. Target nomination
The most important mandate for the SSGCID is to provide three-
dimensional protein structure-determination services to the scientiﬁc
community at no charge. Target nominations from requestors may
be submitted online (at http://www.ssgcid.org/home/Community.asp)
and such nominations are given the highest priority in the SSGCID
pipeline. Since the beginning of the project, 2161 community requests
have been received from 98 groups, of which 1384 have been
approved and 1078 have entered into the SSGCID pipeline (see
Table 2 and Fig. 3). 511 of the requests were received during the
preparation of this manuscript and thus are still being processed for
introduction
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Table 1
SSGCID success rates by taxon.
Taxon Cloned
Soluble
(%)
Puriﬁed
(%)
Crystals
(%)
Diffraction
(%)
Structure
(%)
Overall
(%)
Bacteria 3383 57 60 51 51 66 6
Anaplasma 162 51 72 29 53 100 6
Bartonella 222 64 68 46 71 66 9
Borrelia 161 48 61 49 39 56 3
Brucella 303 61 51 72 64 72 10
Burkholderia 780 54 38† 48 70 69 5†
Ehrlichia 120 72 64 44 58 64 8
Mycobacterium 1503 59 69 53 41 65 6
Rickettsia 104 47 69 47 50 50 4
Other genera‡ 28 50 93 38 80 25 4
Eukaryotes 758 56 71 44 43 61 5
Babesia 28 61 82 71 60 83 18
Coccidioides 65 57 84 52 56 78 11
Cryptosporidium 75 55 68 32 33 33 1
Encephalitozoon 116 66 68 48 28 71 4
Entamoeba 245 49 70 39 58 53 4
Giardia 116 59 88 45 33 56 4
Toxoplasma 81 60 49 42 30 33 1
Other genera§ 32 41 62 38 33 100 3
Viruses 30 47 93 69 44 75 11
Filoviridae§5 2 0 0 0
Orthomyxoviridae 25 52 100 69 44 75 12
Other viruses 7 43 67 50 100 100 14
Total 4178 57 62 50 50 66 6
† The success rate for Burkholderia is artiﬁcially low, since puriﬁcation of a large number
of soluble targets has not yet been completed. ‡ Bacterial and eukaryotic genera with
25 or fewer targets are not shown individually. § Viruses are grouped by family.
Figure 3
Summary of community-request targets by kingdom (pie chart) and genus (tables).submission to NIAID and entry into the pipeline. Included in the
community requests are 770 unique targets internally selected by
SSGCID and subsequently requested by members of the scientiﬁc
community. Consequently, these targets have been converted into
community requests.
3.2. Structures solved
All protein structures solved by SSGCID are submitted to the
Protein Data Bank, while target status and protocols are submitted to
the PSI TargetDB and PepcDB. The 318 structures submitted to the
PDB by SSGCID include 75 structures from 38 different community-
request targets (see Table 2). SSGCID structures provide a previously
unavailable resource for researchers working on many pathogens,
since they represent a substantial portion of all PDB entries for a
number of genera. For example, SSGCID has solved 100% of all PDB
entries for Anaplasma (ten), Ehrlichia (nine) and Rickettsia (six),
87% of all entries for Babesia (seven), 77% of all entries for Brucella
(42), 68% of all entries for Bartonella (22) and 61% of all entries for
Coccidioides (eight).
SSGCID works closely with members of the scientiﬁc community
to publish protein structural data produced by the consortium and
this has resulted in a number of collaborative publications (Yamada et
al., 2010; Edwards et al., 2010; Jaffe et al., 2011; Zhang et al., 2011;
Buchko et al., 2010, 2011; Li et al., 2010a,b; Moreno et al., 2010).
3.3. SSGCID material resources
Clones produced by the SSGCID are made available through the
Biodefense and Emerging Infections Research Resources Repository
(BEIR; http://www.beiresources.org/). To date, over 2600 clones are
available for order and more are deposited each quarter. More than
1400 proteins (puriﬁed as single ﬁnal peaks by size-exclusion
chromatography in 10–150 mg quantities) produced by SSGCID
can be ordered online through the SSGCID Protein Sample
Distrbution System (SSGCID-PSDS). The PSDS site (http://
www.ssgcidproteins.org) is partnered with Emerald BioSystems and
will be accessible from the BEI Resources website by the fall of 2011.
The only cost to the end-user for these proteins is a nominal charge to
cover shipping on dry ice.
4. Future outlook
At the time of writing, the SSGCID has submitted over 300 structures
to the PDB from proteins encoded by bacteria, parasites and viruses
causing human infectious disease. The current rate of solving struc-
tures is approximately two new depositions every week, putting us on
track to exceed the project’s ﬁve-year goal. CSGID, the sister center
to SSGCID, has solved structures at a similar pace. Thus, it is
anticipated that together SSGCID and CSGID will submit over 1000
structures from infectious disease drug targets to the PDB by the end
of the ﬁve-year contract period (late 2012). For many organisms this
represents the vast majority of protein structures available and thus
provides a heretofore unavailable opportunity for researchers to
exploit structure-based drug-design approaches in order to develop
novel chemotherapeutic agents against these diseases. SSGCID is
committed to engaging the infectious disease research community in
collaborations to maximize the potential for exploitation of the
recent advances in structural genomics. The following articles in this
special issue serve to communicate SSGCID’s progress and engender
even more interest from the scientiﬁc community.
5. Overview of following papers
This volume of Acta Crystallographica Section F represents a unique
perspective on the SSGCID, as it is comprised of laboratory and
structure communications prepared entirely by the scientists who
work within the consortium itself. This volume contains several
methodological papers that provide details of the high-throughput
pipeline of the SSGCID: synthetic gene construction with Gene
Composer software, fusion tags and cleavage methods for maximum
yields from large-volume protein expression and specialized instru-
mentation for parallel protein puriﬁcation and crystallization.
Speciﬁcally, Choi and coworkers show that screening for IMAC
recovery (immobilized metal-afﬁnity chromatography) at early high-
throughput screening and later large-scale expression screens help to
identify the proteins that are most likely to be successful in upscaling,
puriﬁcation and crystal trials (Choi et al., 2011). Additionally, Bryan
and coworkers demonstrate that 3C protease cleavage improves the
chances that a given protein will produce a structure (Bryan et al.,
2011). The structure communications in this volume cover a broad
range of Category A, B and C pathogens, including both bacterial
(Rickettsia prowazekii, Ehrlichia chaffeensis and Burkholderia
pseudomallei) and eukaryotic (Giardia lamblia, Coccidioides immitis,
Babesia bovis and Cryptosporidium parvum) pathogens, some of
which represent one of very few protein structures available for the
organism in the PDB. In many instances, these communications
compare the apo structure of a protein with one or more ligand-
bound complexes, including those produced through fragment
screening or obtained using explicit transition-state mimetics. These
comparative structural investigations, both in solution-state and
crystal forms, now serve to enhance the understanding of the catalytic
mechanisms of these targets and provide a basis for asking questions
at the outset of rational structure-based drug-design research.
The authors wish to thank all the members of the SSGCID
scientiﬁc team who have made a special effort for this issue of Acta
Crystallographica Section F. We also thank Christina McCormick for
her outstanding coordination efforts in organizing the manuscripts
for this special issue. This research was funded under Federal
Contract No. HHSN272200700057C from the National Institute of
Allergy and Infectious Diseases, the National Institutes of Health,
Department of Health and Human Services. The research conducted
at PNNL, a facility operated by Battelle for the US Department of
Energy (DOE), was performed primarily at the W. R. Wiley
Environmental Molecular Sciences Laboratory, a national scientiﬁc
user facility sponsored by the US DOE’s Ofﬁce of Biological and
Environmental Research program.
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Table 2
Summary of community-request targets in the SSGCID pipeline.
Community-request targets
Requestors 98
Requests received† 2161
Unique targets approved 1384
Unique targets, work started 1078
PDB submissions
Total unique targets 38
Claimed by requestor before target solved 17
Claimed by requestor after target solved 21
Total unique structures 75
Claimed by requestor before target solved 27
Claimed by requestor after target solved 48
† Includes multiple requests for the same target.References
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